Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
BLSM Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
44.05%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$579.88M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$569.56M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$596.36M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$561.67M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$547.86M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$632.76M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$637.59M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $579.88M | N/A | 44.05% | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 161.13% | 93.89% | 96.07% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 40.62% | 9.52% | -25.24% | -32.61% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -60.79% | -73.94% | -62.04% | -71.62% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.44% | -17.98% | 71.24% | -6.51% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -24.06% | -36.09% | -34.99% | -44.03% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -8.42% | -4.61% | -3.17% | 11.46% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -99.83% | 118.83% | 8.21% | -14.12% |
ROE
N/A
ROA
-37.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 45.97% |
| 2024-12-31 | 42.12% |
